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The lipidation of peptide drugs is one strategy to obtain extended half-lives,
enabling once-daily or even less frequent injections for patients. The half-life
extension results from a combination of self-association and association with
human serum albumin (albumin). The self-association and association with
albumin of two insulin analogues, insulin detemir and insulin degludec, were
investigated by small-angle X-ray scattering (SAXS) and dynamic light
scattering (DLS) in phenolic buffers. Detemir shows concentration-dependent
self-association, with an equilibrium between hexamer, dihexamer, trihexamer
and larger species, while degludec appears as a dihexamer independent of
concentration. The solution structure of the detemir trihexamer has a bent
shape. The stoichiometry of the association with albumin was studied using DLS.
For albumin–detemir the molar stoichiometry was determined to be 1:6
(albumin:detemir ratio) and for albumin–degludec it was between 1:6 and 1:12
(albumin:degludec ratio). Batch SAXS measurements of a 1:6 albumin:detemir
concentration series revealed a concentration dependence of complex formation.
The data allowed the modelling of a complex between albumin and a detemir
hexamer and a complex consisting of two albumins binding to opposite ends of a
detemir dihexamer. Measurements of size-exclusion chromatography coupled to
SAXS revealed a complex between a degludec dihexamer and albumin. Based
on the results, equilibria for the albumin–detemir and albumin–degludec
mixtures are proposed.
1. Introduction
Human serum albumin (albumin) comprises more than half
of the total amount of protein in the blood plasma, with a
concentration of 35–50 mg ml1. Albumin has many impor-
tant physiological functions involving regulation of the
colloidal osmotic pressure and the transport of a variety of
ligands such as physiological metabolites, fatty acids,
hormones, bile acids and drugs (Fanali et al., 2012; Ha &
Bhagavan, 2013; Yang et al., 2014). Albumin has a half-life of
approximately 19 days (Peters, 1985) that arises from binding
to the major histocompatibility complex-related Fc receptor
for immunoglobulin G (FcRn), resulting in a pH-dependent
recycling mechanism. Albumin is thus rescued from degra-
dation in the same manner as immunoglobulin G (Chaudhury
et al., 2003, 2006).
These pharmacokinetic properties are exploited by using
albumin as a vehicle for drug delivery to increase the half-life
of fast-degrading peptides and other smaller molecules. Half-
life extension can be obtained by the chemical conjugation of
a drug to albumin (Bukrinski et al., 2017) or by noncovalent
complexation. One widely applied strategy to obtain
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complexation is lipidation, which exploits the natural affinity
of albumin for fatty acids (Sleep, 2014; Sleep et al., 2013).
Examples of such molecules are the lipidated insulins detemir
and degludec (trade names Levemir1 and Tresiba1, respec-
tively; Novo Nordisk A/S) and the lipidated glucagon-like
peptide-1 analogues liraglutide and semaglutide (trade names
Victoza1 and Saxenda1, and Ozempic1, respectively; Novo
Nordisk A/S).
Detemir and liraglutide are examples of first-generation
lipidated peptides; the half-life of detemir is 5–7 h (Danne et
al., 2003) and that of liraglutide is 13 h (Knudsen et al., 2000).
Optimization of the fatty acids led to the second-generation
products degludec and semaglutide. The half-life of degludec
is 25 h (Heise et al., 2012), while that of semaglutide is
approximately one week (Lau et al., 2015). The extremely long
half-life of semaglutide indicates that the albumin–sema-
glutide complex is so strong that it allows the semaglutide–
albumin complex to be recycled, mediated by the FcRn
receptor.
Apart from complexation with albumin, lipidation can lead
to self-assembly of the peptides in the subcutaneous depot,
resulting in slower diffusion into the bloodstream (Havelund
et al., 2004) or to oligomers circulating in the blood (Freder-
iksen et al., 2015). The overall mechanism whereby the
peptides obtain a longer half-life is a combination of these two
effects, complexation to albumin and oligomerization, where
the importance of each effect differs from peptide to peptide
(Deacon, 2009; Agersø et al., 2002; Jonassen et al., 2012;
European Medicines Agency, 2012; Havelund et al., 2004).
In this study, we use detemir and degludec as models to
investigate the binding of a first-generation and a second-
generation lipidated peptide. Both insulins are used in the
treatment of diabetes mellitus type 1 and type 2, and both are
long-acting lipidated insulin analogues that are used as basal
insulin to control blood sugar levels during fasting. A basal
insulin is combined with a rapid-acting insulin used in
connection with a meal to mimic the nondiabetic response to
energy uptake.
The crystal structure of detemir in the presence of phenol
was determined by Whittingham et al. (1997). The crystal
structure shows that detemir forms dihexamers stabilized by
fatty-acid interactions at the hexamer interface. Whether the
fatty-acid interactions are present in solution or simply an
artefact induced by crystal packing is not clear (Whittingham
et al., 1997). In solution, detemir has previously been shown to
exist in an equilibrium between hexamers and dihexamers
(Havelund et al., 2004), and a recent study using analytical
ultracentrifugation sedimentation velocity showed that
detemir is present in an equilibrium between monomers,
hexamers, dihexamers and trihexamers (Adams et al., 2018).
The binding of detemir to albumin and its mechanism of
protraction was studied by Havelund and coworkers using
size-exclusion chromatography (SEC). They found that
albumin binds to both dimeric and hexameric detemir and
concluded that both the oligomerization into dihexamers and
the interaction with albumin contributed to the prolonged
half-life (Havelund et al., 2004).
The solution structure of degludec has been studied by both
small-angle X-ray scattering (SAXS; Steensgaard et al., 2013)
and analytical ultracentrifugation (Adams et al., 2017, 2018;
Steensgaard et al., 2013). While there is general agreement
that degludec is found as a dihexamer in phenol-containing
solutions, different crystal forms show ambiguous inter-
molecular contacts (Steensgaard et al., 2013).
The binding of degludec to albumin and self-association was
studied by Jonassen et al. (2012) using SEC. They found that
degludec binds to albumin with a 2.4-fold higher affinity than
detemir and forms multihexamers in phenol-free buffer with
Zn2+. The protracted action of degludec mainly results from
multihexamerization in the subcutaneaous depot (Kurtzhals et
al., 2011; Seested et al., 2012; Jonassen et al., 2012) and also to
some extent from albumin binding (European Medicines
Agency, 2012).
Using SAXS in combination with dynamic light scattering
(DLS), we have studied the solution structures of detemir and
degludec alone and in complex with albumin. To our knowl-
edge, these are the first SAXS studies of detemir alone and of
albumin–detemir and albumin–degludec complexes.
2. Materials and methods
2.1. Materials
Proteins were obtained as commercially available products:
insulin detemir (detemir) as Levemir1 and insulin degludec
(degludec) as Tresiba1, both from Novo Nordisk A/S, and
recombinant human serum albumin as Recombumin1 Alpha
or Recombumin1 Elite (formally named AlbIX1) from
Albumedix Ltd.
2.2. SAXS sample preparation
The insulin analogues detemir and degludec were measured
alone and in a mixture. An overview of the samples is given in
Supplementary Table S1. All protein samples were dialyzed
over three shifts using Slide-A-Lyzer1Dialysis Cassettes from
Thermo Scientific. The buffer from the last shift was sterile-
filtered using a 0.2 mm filter and used for sample-dilution and
buffer measurements. All of the buffers that were used are
listed in Table 1. 1 kDa cutoff spin filters were used for
concentration. If possible, protein concentrations were deter-
mined by UV–Vis spectroscopy using a NanoDrop1 1000
spectrophotometer from Thermo Scientific. The extinction
coefficient for albumin was estimated from the sequence as
research papers
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Table 1
Overview of the buffers, listing their constituents, pH and ionic strength
(IS).
Buffer Constituents pH IS (mM)
Bufdet 5 mM Na2HPO4, 15 mM phenol, 13 mM m-cresol,
173 mM glycerol, 20 mM NaCl
7.4 31
Bufalb-det 5–10 mM Na2HPO4, 10–13 mM m-cresol,
11–15 mM phenol, 130–171 mM glycerol,
24–69 mM NaCl
7.4 36–89
Bufdeg 25 mM Na2HPO4, 16 mM m-cresol, 16 mM phenol,
213 mM glycerol, 20 mM NaCl
7.6 76
34 445 M1 cm1 at 280 nm using the ProtParam (Gasteiger et
al., 2005) tool from ExPaSy (Gasteiger et al., 2003). For
protein stocks containing phenol or m-cresol, the concentra-
tions were determined by scaling to SAXS data at a known
concentration or by refractometry using an Anton Paar
Abbemat 550 refractometer with a refractive-index increment,
dn/dc, of 0.19 ml g1.
2.3. SAXS data collection
SAXS experiments were carried out on the I911-SAXS
beamline (Labrador et al., 2013) at the MAX IV Laboratory,
Lund, Sweden and on the EMBL P12 BioSAXS beamline
(Blanchet et al., 2015) at PETRA III, DESY, Hamburg,
Germany. Data-collection parameters are given in Table 2.
The sample-to-detector distance and the direct beam position
were calibrated using silver behenate, and water was measured
to place the data on an absolute scale. The buffer was
measured before and after each sample.
2.4. SEC–SAXS data collection
UV–SEC–SAXS measurements were carried out on the
EMBL P12 BioSAXS beamline (Blanchet et al., 2015) at
DESY using the experimental setup described in Table 2. A
Superdex 200 Increase 10/300 GL column (GE Healthcare
Life Sciences) was used in combination with an Agilent 1260
Infinity Bio-Inert HPLC/FPLC machine with elution through
a UV–Vis spectrophotometer and thereafter directly to the
P12 beamline. 100 ml of sample was injected and the flow rate
of Bufdeg (see Table 1) was set to 0.70 ml min
1. Prior to the
measurements, the column was equilibrated with eight column
volumes.
2.5. SAXS data analysis and modelling
For data collections at the MAX IV Laboratory, all cali-
brations, corrections and data reduction were carried out using
the PyFAI package (Kieffer & Wright, 2013). Buffer aver-
aging and subtraction were performed in PRIMUSqt
(Konarev et al., 2003). For the data collected at EMBL, an
automated pipeline (Blanchet et al., 2015) carried out all data
processing and additionally provided preliminary data
analysis. For the SEC–SAXS data, CHROMIXS (Franke et al.,
2017) was used in automated mode to select buffer and sample
regions and to perform buffer subtraction. For all SAXS
curves the scattering vector is defined as q = 4sin/, where
2 is the scattering angle and  is the wavelength.
The ATSAS program package v.2.8.3 (Franke et al., 2017)
was used for data analysis and modelling. The baseline-
subtracted SAXS curves were investigated for inter-particle
interference by Guinier analysis in PRIMUSqt (Konarev et al.,
2003) and were truncated at low q values if necessary. Pair
distance distribution functions [P(r) functions] were calcu-
lated by GNOM (Svergun, 1992). Molecular parameters were
obtained from Guinier analysis and calculated P(r) functions.
Molecular masses (MMs) were calculated as MM = [NAI(0)/c]/
M
2 , where I(0)/c is the concentration-normalized forward
scattering, NA is the Avogadro constant and M is the
scattering contrast per mass. The average partial specific
volume for proteins of 0.7425 cm3 g1 determined by Mylonas
& Svergun (2007) was used to calculate M. The MM in kDa
was, furthermore, estimated from the Porod volume (Vp) in
nm3 by the relation Vp/MM = 1.50 (Trewhella et al., 2017).
Prior to ab initio modelling, AMBIMETER (Petoukhov &
Svergun, 2015) was run in order to assess the ambiguity of the
modelling. DAMMIF (Franke & Svergun, 2009) was used to
calculate ab initio models in interactive mode with a dummy-
atom radius of 2.7 A˚ and standard settings unless otherwise
specified. To generate models with P2 symmetry, DAMMIN
(Svergun, 1999) was used with prolate anisometry across the
symmetry axis. DAMMIN was used because it is not possible
to specify a direction of anisometry with DAMMIF, and the
models that were generated without constraining it resulted in
an undesired direction of symmetry. For each curve, 20 models
were calculated; they were subsequently aligned and averaged
using the DAMAVER program suite (Volkov & Svergun,
2003) and clustered using DAMCLUST (Petoukhov et al.,
2012). The resolution of the models was determined using
SASRES (Tuukkanen et al., 2016). The most typical model of
the ensemble or a cluster was chosen as the representative.
For rigid-body modelling, SASREFCV (Petoukhov &
Svergun, 2005, 2006; SASREF) was run using standard
settings for X-ray data on the first 80% of the scattering curve.
The fits of the models to the experimental data were calcu-
lated with CRYSOL (Svergun et al., 1995) using 500 points in
the theoretical curve and fitting up to qmax = 0.4 A˚
1 with
constant background subtraction. The subunits used in rigid-
body modelling were crystal structures downloaded from the
Protein Data Bank (PDB).
Both insulin and albumin exist in different conformations.
Albumin changes conformation upon the binding of fatty
acids (Ascenzi & Fasano, 2010), while insulin and detemir
(Olsen & Kaarsholm, 2000) hexamers can exist in R6, T3R3 or
T6 conformations depending on the binding of phenolic
ligands. Therefore, a fatty-acid-free (PDB entry 1ao6; Sugio et
al., 1999) and a fatty-acid-bound albumin structure (PDB
entry 1bj5; Curry et al., 1998) were used in combination with
R6, T3R3 and T6 insulin hexamers [PDB entries 1ev3 (Smith et
al., 2000), 1trz (Ciszak & Smith, 1994) and 1mso (Smith et al.,
2003), respectively]. The insulin crystal structures are not
lipidated, and it is assumed that the effect of lipidation is
negligable in rigid-body modelling. When necessary, symmetry
operations were applied to the structures to generate
hexamers. To generate dihexamers, the hexamers were trans-
research papers
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Table 2
Experimental setup of SAXS experiments.
Instrument
I911-SAXS, MAX II,
MAX IV Laboratory
P12, PETRA III,
DESY
Detector PILATUS 1M PILATUS 2M
Wavelength (A˚) 0.9100 1.241
q-range (nm1) 0.0829–5.406 0.0248–5.036
Exposure time (s) 4  30 20  0.05
Temperature (K) 293 293
Sample-to-detector distance (mm) 1962.110 3000
lated along the z axis in steps of 0.1 A˚. The dihexamers
were fitted to the degludec data with CRYSOL in order to
determine the conformation and the optimal inter-hexameric
distance. The best fit was obtained with an R3T3–T3R3
dihexamer at an inter-hexameric distance of 35.4 A˚ (Supple-
mentary Fig. S1), which is in agreement with previous findings
by Steensgaard et al. (2013). The different insulin conforma-
tions were not distinguishable in the rest of the data and
resulted in very similar fits. Based on this, the models gener-
ated with the T3R3 hexamer and the R3T3–T3R3 dihexamer
were used. Likewise, the models generated with fatty-acid-free
and fatty-acid-bound albumin showed similar fits to the data.
We chose to use the models generated with fatty-acid-bound
albumin, as we expect the binding of detemir and degludec to
induce a conformational change similar to that induced by
fatty-acid binding since both insulin analogues are lipidated.
Details of the generated ab initio and rigid-body models are
reported in Supplementary Table S8 in the format proposed
by the updated SAXS publication guidelines (Trewhella et al.,
2017). The ab initio modelling is also described in further
detail in the supporting information. Both SAXS data and
models have been deposited in the Small Angle Scattering
Biological Database (see Table S8; https://www.sasbdb.org/;
Valentini et al., 2015).
SEC–SAXS was not available at the time of the detemir
experiments, and the modelling was performed on poly-
disperse data. OLIGOMER (Konarev et al., 2003) was used to
estimate the volume fractions of the different species in the
samples with a form-factor file as input. The file was produced
by FFMAKER (Konarev et al., 2003) using CRYSOL with
standard settings and 256 points in the theoretical scattering
curve. For the albumin–detemir samples, the molar stoichio-
metries were used as constraints in FFMAKER. OLIGOMER
was run with a maximum scattering vector qmax = 0.4 A˚
1 and
the addition of a constant component. The structures used as
input were albumin, insulin monomer, dimer, hexamer and
dihexamer, and the rigid-body models of the insulin trihex-
amer, albumin–hexamer, albumin–dihexamer and albumin–
dihexamer–albumin complexes.
2.6. DLS data collection and analysis
DLS experiments were carried out to determine the stoi-
chiometries of the albumin–detemir and albumin–degludec
complexes. Albumin was mixed with detemir and degludec,
respectively, while keeping the total protein mass concentra-
tion constant. The mole fraction of albumin was calculated by
treating the detemir/degludec hexamer as an entity.
For the albumin–detemir samples, a total protein concen-
tration of 14.2 mg ml1 was used. For the albumin–degludec
samples, a total protein concentration of 10 mg ml1 was used.
A DynaPro DLS plate reader (Wyatt Technology, Santa
Barbara, California, USA) was used for the measurements
and the Wyatt DYNAMICS software was used for data
collection and analysis. 100 ml of each sample was loaded onto
a 96-well nonbinding Corning1 microplate and centrifuged
for 2 min at 2000 rev min1 to remove air bubbles. Each
sample was measured ten times for 5 s. The measurements
were carried out at 298 K and in triplicate. The viscosities and
the refractive indices of the solvents were calculated using the
Zetasizer software v.7.1 (Malvern Instruments, Worcestershire,
England) and used in data analysis. Z-average sizes obtained
by cumulants analysis are reported in the results.
2.7. Figures
All figures were prepared using PyMOL (v.1.8.2.3; Schro¨-
dinger) and all plots were prepared by MATLAB (v.9.1; The
MathWorks, Natick, Massachusetts, USA).
3. Results
3.1. SAXS insulin oligomers
The scattering curves from the concentration series of
detemir and degludec are presented in Fig. 1. Molecular
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Figure 1
Scattering curves, normalized for concentration, of (a) degludec (0.5–
7.7 mg ml1) and (b) detemir (0.5–9.9 mg ml1); darker shades corre-
spond to higher concentrations. The arrows illustrate changes with
increasing concentration.
parameters were derived from the curves and are presented in
Supplementary Tables S2 and S3.
3.1.1. Degludec. For the degludec curves, we observed no
concentration-dependent change in the overall curve shape
(q  0.04 A˚1; Fig. 1a). For q < 0.04 A˚1 a decrease in the
normalized forward scattering [I(0)/c] was observed with
increasing protein concentration, indicating repulsion. To
obtain an ideal scattering curve, low- and high-concentration
data were merged to avoid repulsion artefacts at high
concentrations. The SAXS-derived MM ranges from 12 to 13
monomers, corresponding to a dihexamer (Supplementary
Fig. S1).
3.1.2. Detemir. For the detemir curves, we observed an
increase in curve steepness from q = 0.05 to 0.12 A˚1 with
increasing concentration (Fig. 1b). The change in the shape of
the curve indicates concentration-dependent oligomerization.
Repulsion was observed at higher concentrations as a flat-
tening of the curves for low q values. MM ranges from 17 to 22
monomers, and the increase is consistent with an increase in
the Porod volume (Supplementary Table S3).
Until recently, the highest oligomer of detemir reported was
a dihexamer in equilibrium with a hexamer (Havelund et al.,
2004), but in 2018 Adams and coworkers reported detemir in a
trihexameric state in equilibrium with monomers, hexamers
and dihexamers (Adams et al., 2018).
We chose the 2.5 mg ml1 curve for modelling the detemir
trihexamer as it was unaffected by repulsion and had an MM
close to that expected for a trihexamer. Ten rigid-body models
were generated by SASREF with three hexamers as input. In
Fig. 2, the best model is superimposed onto the representative
ab initio model generated by DAMMIF (42 3 A˚ resolution).
The ab initio and rigid-body models overlap nicely, which gives
confidence in the modelled trihexamer. The model fits the data
well, with 2 = 1.16 (Fig. 2a).
To assess the equilibria in the concentration series, we ran
OLIGOMER with PDB structures of the insulin monomer,
dimer, hexamer and dihexamer, and the model of the trihex-
amer. The results are presented in Table 3 and the fits to the
experimental data are shown in Fig. 3. The lower concentra-
tion samples, 0.5 and 1.0 mg ml1, consist of an equilibrium
between hexamer, dihexamer and trihexamer. The
research papers
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Figure 2
Modelling results of the detemir trihexamer based on the 2.5 mg ml1
detemir scattering curve. (a) Fit of the rigid-body model (green) to the
experimental data (grey). (b) shows an error-weighted residual plot of the
model. (c) The rigid-body model (green) is superimposed onto the low-
resolution ab initio model (light blue).
Table 3
OLIGOMER results for detemir samples.
Results are for detemir samples in the concentration range 0.5–2.5 mg ml1,
showing volume fractions of the species with uncertainties in the last digit in
parentheses and 2 fits to experimental data.
Concentration (mg ml1) 2 Hexamer Dihexamer Trihexamer
0.5 0.64 0.07 (3) 0.13 (3) 0.80 (3)
1.0 0.66 0.05 (1) 0.10 (2) 0.85 (1)
2.5 1.23 0.016 (5) 0.984 (5)
Figure 3
OLIGOMER results for detemir samples in the concentration range 0.5–
2.5 mg ml1. (a) OLIGOMER fits are plotted (green; darker shades
correspond to higher concentrations) with the experimental scattering
curves (grey). The scattering curves have been shifted on the I(q)/c axis
for clarity. (b) shows an error-weighted residual plot of the fits.
2.5 mg ml1 curve is almost monodisperse, with 98.4%
trihexamer and 1.6% dihexamer. For the higher concentration
samples, the OLIGOMER results do not fit the experimental
data (data not shown), reflecting that higher oligomers are
needed to describe the data. This is supported by a steeper
decrease in their scattering curves around q = 0.05–0.10 A˚1 in
Fig. 1(b).
3.2. DLS of albumin complexes
DLS experiments were set up to determine the binding
stoichiometry between albumin and detemir and degludec,
respectively. In the experiments, the mass fraction was varied,
the molar stoichiometry was calculated and the maximum
measured radius of hydration (Rh) was considered to repre-
sent the stoichiometry of the protein complex (Hanlon et al.,
2010).
The results are presented in Fig. 4, in which selected molar
ratios are marked on the top x axis. For detemir, a peak in Rh
is observed close to a 1:6 molar ratio. For degludec, the
maximum in Rh is more flat and is observed between ratios of
1:12 and 1:6.
3.3. Albumin–degludec complex structure
Based on the maximum in Rh between molar ratios of 1:6
and 1:12, albumin–degludec complex formation was investi-
gated at both ratios. The scattering curves of the albumin–
degludec mixtures are shown in Fig. 5 and their SAXS-derived
molecular parameters are given in Supplementary Tables S4
and S5.
The shapes of the scattering curves for the 1:12 mixtures
(Fig. 5a) do not change with protein concentration. The MM
values derived from the data were 138–141 kDa, corre-
sponding to a monodisperse 1:12 complex (MM = 140 kDa).
The overall shape of the 1:6 scattering curves (Fig. 5b) also
does not change with concentration, except for an increase in
I(0)/c corresponding to attractive interactions at higher
concentrations. The MM values derived from the 1:6 data
range between 145 and 163 kDa; they do not correspond
directly to monodisperse 1:6, 1:12 or 2:12 complexes (MM
values of 103, 140 and 206 kDa, respectively), but rather to a
mixture of different species. In order to separate the species, a
SEC–SAXS experiment was conducted.
The SAXS intensity trace of the SEC–SAXS run is shown in
Fig. 6(a) with two apparent peaks. The scattering curve of the
lowest MM peak (SEC–SAXSalbumin) is shown in Fig. 6(b)
and overlaps very well with a batch SAXS measurement
of albumin. The scattering curve of the higher MM peak
research papers
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Figure 4
Results of DLS experiments on albumin–detemir (blue triangles) and
albumin–degludec (olive squares) mixtures. The average hydrodynamic
radius is plotted as a function of the molar fraction of albumin in the
mixtures. The upper x axis indicate the molar ratio between albumin and
either detemir or degludec. The error bars represent standard deviations.
Figure 5
Scattering curves, normalized for concentration, of albumin and degludec
mixed in (a) 1:12 and (b) 1:6 ratios; darker shades correspond to higher
concentrations.
(SEC–SAXSalbumin–degludec) is shown in Fig. 6(c) and overlaps
very well with a 1:12 albumin–degludec batch SAXS
measurement. The MM value derived from the curve is
141 kDa, which could correspond to an albumin–dihexamer or
a hexamer–albumin–hexamer complex (both with an MM of
140 kDa). These complexes will be modelled in the following
section based on the SEC–SAXSalbumin–degludec curve.
In addition to the two apparent peaks in the chromatogram,
a small shoulder consisting of two peaks is present on the left
side of the main peak, which explains the higher MM for the
1:6 mixture and corresponds to larger protein complexes.
3.3.1. Rigid-body modelling of the albumin–dihexamer
complex. Ten rigid-body models were generated by SASREF
based on the SEC–SAXSalbumin–degludec curve with albumin and
two hexamers as input in order to test whether the hexamers
bind albumin separately or as a dihexamer. We found that the
hexamers in the best-fitting model formed a dihexamer, thus
suggesting an albumin–dihexamer complex. Ten rigid-body
models were therefore generated with albumin and a dihex-
amer as input. The best of these ten models fitted the data well
with 2 = 1.74 (Fig. 7a) and showed good agreement with the
representative ab initio model generated by DAMMIF (41 
3 A˚ resolution; Fig. 7c). In the complex, the dihexamer binds
close to Sudlow’s site I, which is one of the major drug-binding
sites in albumin and overlaps with fatty-acid-binding site 7
(FA7; Sudlow et al., 1975).
3.4. Albumin–detemir complex structures
The scattering curves of the albumin–detemir samples are
shown in Supplementary Fig. S2. Clearly, the curves are
affected by concentration-dependent equilibria.
Two of the obtained SAXS curves were used for modelling:
the 8.5 mg ml1 SAXS curve with an MM of 104 kDa, which
could correspond to an albumin–hexamer complex (MM of
102 kDa), and the 15.6 mg ml1 SAXS curve with an MM of
213 kDa, which could correspond to an albumin–dihexamer–
albumin complex (MM of 204 kDa). These curves are shown
in Fig. 8.
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Figure 7
Modelling results of the albumin–dihexamer complex based on the SEC–
SAXSalbumin–degludec scattering curve. (a) Fit of the rigid-body model
(orange) to the experimental data (grey). (b) shows an error-weighted
residual plot for the model. (c) The rigid-body model is shown with
albumin in grey and the dihexamer in orange. It is superimposed onto the
low-resolution ab initio model (light blue).
Figure 6
SEC–SAXS results for albumin and degludec mixed in a 1:6 ratio. (a) Plot
showing average intensity and MM as a function of column volume, with
peaks marked in yellow and red. (b) Scattering curve (SEC-SAXSalbumin)
of the peak at 13.2 ml (red) shown with a batch scattering curve for
albumin at 2.8 mg ml1 (grey). (c) Scattering curve (SEC-SAXSalbumin) of
the peak at 11.7 ml (yellow) and a batch scattering curve for albumin–
degludec in a 1:12 ratio at 6.5 mg ml1 (grey). All scattering curves are
normalized for concentration.
The curves overlap well at q-values above 0.05 A˚1 (2 =
0.91), indicating that common local features are present in
both complexes, while the higher concentration curve has
higher intensity at lower q-values, thus corresponding to a shift
in the equilibrium towards larger complexes with larger
intramolecular distances.
3.4.1. Rigid-body modelling of the albumin–hexamer
complex. Ten rigid-body models were generated by
SASREF based on the 8.5 mg ml1 albumin–detemir curve
with albumin and a detemir hexamer as input. These ten
models could be clustered into two groups based on the
binding position on albumin: near Sudlow’s site I and near
Sudlow’s site II. The best model of each cluster and their fits to
experimental data (2 = 1.32 and 2 = 1.88, respectively) are
shown in Fig. 9 with the representative ab initio model
(393 A˚). The 2 values of the clusters do not differ very
much (Figs. 9a and 9b) when considering that the conforma-
tions of albumin and detemir might change upon binding.
3.4.2. Rigid-body modelling of the albumin–dihexamer–
albumin complex. Based on the MM from the 15.6 mg ml1
albumin–detemir SAXS curve, the complex could consist of
two albumins and either two hexamers or one dihexamer. Ten
rigid-body models were generated with P1 symmetry using
two albumins and a dihexamer as input structures, and ten
models were generated with P2 symmetry using an albumin
and a hexamer as input structures.
The best results with P1 (2 = 1.01) and P2 (2 = 1.12)
symmetry and their fits to the experimental data are presented
in Fig. 10, where the rigid-body models are superimposed onto
the representative P1 and P2 ab initio models (53  4 and 55
 4 A˚ resolution, respectively). In both rigid-body models
detemir forms a dihexamer with one albumin bound to each
hexamer and the albumins appear to bind diagonally to the
dihexamer.
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Figure 9
Modelling results of the albumin–hexamer complex based on the
8.5 mg ml1 albumin–detemir scattering curve. (a) Fit of rigid-body
models binding to Sudlow’s sites I (purple) and II (magenta) to the
experimental data (grey). (b) shows error-weighted residual plots for the
models. The rigid-body models are shown in (c) and (d), respectively, with
albumin in grey and the same colour coding as in (a) for the hexamers.
Both models are superimposed on the low-resolution ab initio model
(light blue).
Figure 8
Scattering curves, normalized for concentration, of albumin and detemir
mixed in a 1:6 molar ratio with total protein concentrations of 8.5 and
15.6 mg ml1.
Figure 10
Modelling results of the albumin–dihexamer–albumin complex based on
the 15.6 mg ml1 albumin–detemir scattering curve. (a) Fit of rigid-body
models generated with P1 (light blue) and P2 symmetry (blue),
respectively, to the experimental data (grey). (b) shows error-weighted
residual plots for the models. The rigid-body models are shown in (c) (P2
symmetry) and (d) (P1 symmetry) with albumins in grey and the same
colour-coding as in (a) for the dihexamers. Both models are superimposed
onto the low-resolution ab initio model (light blue).
3.4.3. Analysis of albumin–detemir equilibrium. To assess
the equilibria in the albumin–detemir concentration series,
OLIGOMER was run. The results are summarized in Table 4
and the fits to the experimental data are shown in Fig. 11.
For the lower concentration samples at 1.9 and 4.1 mg ml1,
we observe an equilibrium between albumin, trihexamer and
the albumin–hexamer complex. At 8.5 mg ml1, the equili-
brium shifts towards albumin–dihexamer complexes and the
sample consists of albumin, albumin–hexamer and albumin–
dihexamer complexes. At 15.6 mg ml1, the sample consists
entirely of the albumin–dihexamer–albumin complex. For the
highest concentration sample at 20.8 mg ml1, the
OLIGOMER result does not fit the data (data not shown),
which indicates that larger species are needed to describe the
curve.
4. Discussion
In agreement with previous studies (Steensgaard et al., 2013;
Adams et al., 2018; Havelund et al., 2004), we find degludec as
a dihexamer in phenol-containing buffer and detemir in a
concentration-dependent equilibrium between hexamers,
dihexamers, trihexamers and possibly larger multihexamers.
We present the first structure of the detemir trihexamer, which
has previously only been reported in a study using analytical
ultracentrifugation (Adams et al., 2018). Surprisingly, the
trihexamer has a bent shape.
For degludec mixed with albumin, DLS data showed that
the binding stoichiometry of an albumin–degludec complex
was somewhere between 1:6 and 1:12. However, SAXS
measurements, both inline SEC–SAXS on a 1:6 albumin–
degludec mixture and batch measurements on a 1:12 mixture,
unambiguously showed a 1:12 complex.
For detemir mixed with albumin, we determined the
stoichiometry to be 1:6 by DLS. We succeeded in modelling
an albumin–hexamer complex despite the somewhat
polydisperse curve, as well as an albumin–dihexamer–albumin
complex.
4.1. Equilibria
The different complexes of detemir and degludec with
albumin can thus be directly linked to their oligomeric states.
We propose that detemir and degludec hexamers mixed with
albumin exist in the equilibria illustrated in Fig. 12. Degludec
alone exists as a dihexamer. When mixed with albumin in a
1:12 ratio, the sample purely consists of albumin–dihexamer
complex. Detemir alone exists in an equilibrium with various
oligomers. When mixed with albumin, we observe the
formation of 1:6, 1:12 and 2:12 complexes, with higher protein
concentrations and ionic strengths favouring larger complexes.
At the highest protein concentration, however, we observe an
increase in the MM beyond the expected value for a 2:12
complex, which could be owing to larger complexes.
The differences between the behaviour of degludec and
detemir in solution are solely owing to the different fatty-acid
moieties, as the molecules are otherwise identical. The
different multihexamerizations indicate that their modes of
hexamer–hexamer association are fundamentally different.
The driving force of association results from their fatty-acid
moieties, as human insulin is normally observed in an equi-
librium between monomer, dimer and hexamer (Frankaer et
al., 2017; Jorgensen et al., 2011). While detemir has a C14 fatty
acid attached to LysB29, the second-generation product
degludec has a C16 dicarboxylic fatty acid attached through a
-glutamate linker. The differences in these fatty-acid
moieties mean that degludec has a longer fatty-acid chain and
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Figure 11
OLIGOMER results for albumin–detemir samples in the concentration
range 1.9–15.6 mg ml1. (a) OLIGOMER fits are plotted (red; darker
shades correspond to higher concentrations) with the experimental
scattering curves (grey). The scattering curves have been shifted on the
I(q)/c axis for clarity. (b) shows an error-weighted residual plot of the fits.
Table 4
OLIGOMER results for albumin–detemir samples.
OLIGOMER results for albumin–detemir samples in the concentration range
1.9–15.6 mg ml1, showing volume fractions of the species with uncertainties
in parentheses and 2 fits to experimental data.
Concentration
(mg ml1) 2 Albumin Trihexamer
Albumin–
hexamer
Albumin–
dihexamer
Albumin–
dihexamer–
albumin
1.9 0.57 0.497 (7) 0.257 (3) 0.25 (1)
4.1 0.87 0.477 (4) 0.246 (2) 0.277 (5)
8.5 0.77 0.184 (6) 0.44 (2) 0.36 (1) 0.010 (2)
15.6 2.05 1.000 (1)
two extra negative charges, allowing different interactions.
Therefore, it is likely that the binding of detemir and degludec
albumin probably differs significantly at the atomic level.
5. Conclusion
Here, we have shown that detemir and degludec exist in
different equilibria in phenol-containing buffers and how
these equilibria affect their complex formation with albumin.
We have presented the solution structures of the detemir
trihexamer and of 1:6, 1:12 and 2:12 complexes between
albumin and two insulin analogues. The solution structures are
the first structures of complexes between albumin and long-
acting insulin analogues to be presented.
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